EM2506G "T-Cell Based Therapies in Multiple Myeloma" (IM GR-062725)

Purpose and Overview

This lecture will provide an overview of emerging T-cell–based therapies in multiple myeloma, including CAR-T cells and bispecific antibodies, with a focus on their mechanisms, clinical impact, and evolving role in treatment. Attendees will gain a practical understanding of these novel therapies, their associated toxicities such as cytokine release syndrome and neurotoxicity, and key considerations for managing patients receiving them across the care continuum.

Target Audience

UT Southwestern faculty, fellows, residents and medical students, community physicians, nurse clinicians, physician assistants and nurses.

Learning Objectives

At the conclusion of this activity, the participant should be able to:

  • Understand the basic role of T-cell–based therapies (CAR-T and bispecifics) in treating multiple myeloma.
  • Recognize the most common side effects, including cytokine release syndrome and neurologic symptoms.
  • Identify when to suspect complications and know when to involve oncology or escalate care.
Course summary
Available credit: 
  • 1.00 AMA
Course opens: 
06/30/2025
Course expires: 
07/30/2025
Cost:
$0.00
Rating: 
0

Photo: First Last, M.D.
Aimaz Afrough, M.D
Assistant Professor of Internal Medicine
Division of Hematology & Oncology

Available Credit

  • 1.00 AMA

Price

Cost:
$0.00
Please login or create an account to take this course.

Required Hardware/software

Activities should be run with recent versions of common browsers, including Internet Explorer, Firefox and Google Chrome